"Development of Heterobifunctional Degraders of TDP-43 as a Novel Therapeutic Strategy for Amyotrophic Lateral Sclerosis (ALS)"

This is project is in collaboration with Dr. Alison Axtman at UNC (co-PI)

“Defining the effect of a rare CD44 mutation in Alzheimer's Disease”

PI:  May Khanna

Co-I:  Matt Heuntelman

​

This pilot project seeks to establish the role of a rare mutation in AD.

“Identify small molecule inhibitors to block protein-protein interactions from AMP-AD targets”

PI:  May Khanna

​

The Arizona Alzheimer's Consortium (AAC) is the nation's leading model of statewide collaboration in Alzheimer's disease research. Established in 1998, the Consortium capitalizes on its participating institutions' complementary strengths in brain imaging computer science, genomics, the basic and cognitive neurosciences and clinical and neuropathology research to promote the scientific understanding and early detection of Alzheimer's disease and find effective disease-stopping and prevention therapies. It also seeks to educate Arizona residents about Alzheimer's disease, research progress in the state and the resources needed to help patients, families and professionals manage the disease. The Consortium is determined to find effective treatments to halt the progression and prevent the onset of Alzheimer's disease in the next 12 years.

“Identify small molecule inhibitors to block protein-protein interactions from AMP-AD targets”

​

Collaboration with Lara Mangravite (Sage Bionetworks), Opher Gileadi (Oxford, UK) and Paul Brennan (Oxford, UK).

​

The central goal of the Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD) Target Discovery and Preclinical Validation Project is to shorten the time between the discovery of potential drug targets and the development of new drugs for Alzheimer’s disease treatment and prevention, by integrating the analyses of large-scale molecular data from human brain samples with network modeling approaches and experimental validation.

“Small Molecules Targeting TDP-43-RNA Interactions in ALS”

PI:  Daniella Zarnescu

Co-PI:  May Khanna,  Vijay Gokhale, Rita Sattler

​

The ALSRP is guided by a vision to improve treatment and find a cure for ALS. Through its award mechanisms and funding recommendations, the ALSRP specifically supports innovative preclinical research targeting development of new therapeutics for ALS.

“Small Molecule Restoration of Translation Dysregulation in ALS”

PI:  May Khanna

​

The Arizona Disease Control Research Commission was established by the Arizona Legislature and signed into law by Governor Bruce Babbitt in 1994. ADCRC’s mission was to fund investigators focused on diseases and health issues that impact the residents of Arizona. In 2005, the Arizona Disease Control Research Commission changed its name to the Arizona Biomedical Research Commission. 

“Translation dysregulation in neurodegeneration”

PI:  Daniella Zarnescu

Collaborator:  May Khanna